September 09, 2021
1 min read
Save
Patient enrollment finalized for Stuart’s phase 2 dry eye disease trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Stuart Therapeutics has completed patient enrollment in a phase 2 clinical trial of ST-100 for the treatment of dry eye disease.
The drug candidate is based on PolyCol, a synthesized polypeptide tissue reparative platform.
The multicenter, randomized, double-masked, placebo-controlled study will examine the efficacy and safety of the drop in 150 patients with dry eye disease. Two dose levels of ST-100 will be compared with placebo.
“Today’s ‘last-patient-in’ announcement is a major milestone for our company,” Eric Schlumpf, Stuart’s president and CEO, said in a press release. “This is another important step in the development of the PolyCol platform for ophthalmic indications.”
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.